
Keywords: Clinical trials; Biomarkers; Diarrhea; Notch signaling; Monoclonal antibodies (mAbs); γ-Secretase inhibitorsADAM, a disintegrin and metalloproteases; CR, complete response; CSCs, cancer stem cells; DLL, Delta-like ligand; DLT, dose limiting toxicity; EDTA